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A major challenge in today’s competitive landscape of biotechnology development is to discover and develop 
new drugs more rapidly; increasing the opportunities to discover new therapies successful in the treatment of 
unmet needs for patients. Currently, widely used bench scale bioreactor systems require much user 
manipulation, a large amount of raw materials, and have a long turnaround time for reactor cleaning and 
rebuilding. New technologies such as robotic disposable bioreactor systems pose a solution to the industry’s 
high throughput need. The Ambr® 250 offers such a solution, with 24x250mL bioreactors controlled 
independently. Although this new technology is rapidly being adopted by several groups as a way to increase 
efficiency and speed within upstream development, little data has been collected characterizing these 
bioreactors as scale-down systems of larger vessels used in manufacturing suites. 
 
The aim of this work is to characterize the engineering environment of the Ambr® 250 with a view of defining its 
role in industrial cell culture process development and scale-up. CFD modeling of the Ambr 250 mammalian 
vessel with validation via Particle Image Velocimetry (PIV) was conducted to simulate the hydrodynamic 
environment in the vessel. These findings were evaluated against current benchtop models and manufacturing 
scales. Cultures were run utilizing different engineering parameters (vvm, P/V, kLa) to assess the scalability of 
the current system. Cell growth, production, and product quality were compared across to recommend operating 
conditions for the Ambr® 250 that best match manufacturing scale reactors. Multiple CHO host cell lines were 
examined in order to find optimal operating conditions for the Ambr® 250 system. 
   
 
 
 
 
 
 
 
 
 
 
 
